Andreas Meyerhans

Andreas Meyerhans

Universitat Pompeu Fabra

Life & Medical Sciences

University Education - 1987 PhD in Chemistry, University of Hamburg, Germany. - 1982 Diploma in Chemistry, University of Hamburg, Germany. Professional Positions - Since 2010 ICREA Research Professor at Pompeu Fabra University, Barcelona. - 1998-2009 Full Professor, Saarland University, Germany. - 1990-1998 Assistant Professor, University of Freiburg, Germany. - 1988-1990 Postdoctoral Fellow, Institute Pasteur, Paris, France. - 1987-1988 Postdoctoral Fellow, Institute Biotechnological Research, Braunschweig, Germany.

Research interests

Infections with non-cytopathic viruses usually have 2 different outcomes. They may be eliminated by host immune responses (acute infections) or they may persist lifelong (persistent infections). Medically important examples are the Hepatitis B virus (HBV), the Human Immunodeficiency virus (HIV) and the Hepatitis C virus (HCV) that in adults usually follow an acute (HBV), a persistent (HIV) or an either acute or persistent (HCV) infection course. My laboratory is interested (i) to understand the factors that regulate the decision between an acute versus a persistent infection course, (ii) to define the factors that control the dynamic balance of virus expansion and immune control in persistent infections, and (iii) to generate quantitative descriptions of the virus/immune system dynamics by mathematical modeling.

Selected publications

- Shcherbatova O, Grebennikov D, Sazonov I, Meyerhans A, Bocharov G 2020, 'Modeling of the HIV-1 Life Cycle in Productively Infected Cells to Predict Novel Therapeutic Targets', Pathogens, 9, 4, 255.

- Garcia de Abajo FJ, Hernandez RJ, Kaminer I, Meyerhans A, Rosell-Llompart J, Sanchez-Elsner T 2020, 'Back to Normal: An Old Physics Route to Reduce SARS-CoV-2 Transmission in Indoor Spaces', Acs Nano, 14, 7, 7704 - 7713.

- Bocharov G, Casella V, Argilaguet J, Grebennikov D, Guerri-Fernandez R, Ludewig B, Meyerhans A 2020, 'Numbers Game and Immune Geography as Determinants of Coronavirus Pathogenicity', Frontiers In Cellular And Infection Microbiology, 10, 559209.

- Gonzalez-Cao M, Morán T, Dalmau J, Garcia-Corbacho J, Bracht JWP, Bernabe R, Juan O, de Castro J, Blanco R, Drozdowskyj A, Argilaguet J, Meyerhans A, Blanco J, Prado JG, Carrillo J, Clotet B, Massuti B, Provencio M, Molina-Vila MA, Mayo de Las Casa C, Garzon M, Cao P, Huang CY, Martinez-Picado J, Rosell R 2020, 'Assessment of the feasibility and safety of Durvalumab for the treatment of solid tumours in patients with HIV-1 infection: The phase 2 DURVAST study' JAMA Oncol. 6(7):1063-1067.

- Prochnow H, Rox K, Birudukota NVS, Weichert L, Hotop SK, Klahn P, Mohr K, Franz S, Banda DH, Blockus S, Schreiber J, Haid S, Oeyen M, Martinez JP, Süssmuth RD, Wink J, Meyerhans A, Goffinet C, Messerle M, Schulz TF, Kröger A, Schols D, Pietschmann T, Brönstrup M 2020, 'Labyrinthopeptins exert broad-spectrum antiviral activity through lipid-binding-mediated virolysis' , J Virol. 94(2):e01471-19.

- Huerga Encabo H, Traveset L, Argilaguet J, Angulo A, Nistal-Villan E, Jaiswal R, Escalante CR, Gekas C, Meyerhans A, Aramburu J, Lopez-Rodriguez C 2020, 'The transcription factor NFAT5 limits infection-induced type I interferon responses', Journal Of Experimental Medicine, 217, 3.

Selected research activities

Topic editor on “Mathematical Modeling of the Immune System in Homeostasis, Infection and Disease” for Frontiers in Immunology.